A new weight loss pill is here and it could reshape the GLP-1 market

A new GLP-1 pill is about to hit the market. On Wednesday, Eli Lilly announced its new GLP-1 pill, Foundayo, was approved by the Food and Drug Administration (FDA) for use in adults with obesity or weight-related health problems. The company says that drug trials saw patients taking Foundayo losing an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with a placebo. It said the drug will be available via LillyDirect, noting that it will begin accepting prescriptions immediately. It expects shipping to begin on April 6, and said the drug will be made broadly available “through U.S. retail pharmacies and telehealth providers” soon after. The medication will offer a new needle-free GLP-1 alternative for those who are more comfortable taking a pill. “People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they